Publication Database

Therapierelevante Antibiotikaresistenzen im One-Health-Kontext:
therapy-relevant antibiotic resistances in a One Health context (2023)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Werner, Guido

Abu Sin, Muna

Bahrs, Christina

Brogden, Sandra

Feßler, Andrea (WE 7)

Hagel, Stefan

Kaspar, Heike

Köck, Robin

Kreienbrock, Lothar

Krüger-Haker, Henrike (WE 7)

Maechler, Frederike

Noll, Ines

Pletz, Mathias W.

Tenhagen, Bernd-Alois

Schwarz, Stefan (WE 7)

Walther, Birgit

Mielke, Martin

Quelle

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Bandzählung: 66

Heftzählung: 6

Seiten: 628 – 643

ISSN: 1436-9990

Verweise

URL (Volltext): https://pubmed.ncbi.nlm.nih.gov/37184673/

DOI: 10.1007/s00103-023-03713-4

Pubmed: 37184673

Kontakt

Institut für Mikrobiologie und Tierseuchen

Robert-von-Ostertag-Str. 7-13
14163 Berlin
+49 30 838 51843 / 66949
mikrobiologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

One Health refers to a concept that links human, animal, and environmental health. In Germany, there is extensive data on antibiotic resistance (AMR) and multidrug-resistant (micro)organisms (MDRO) in human and veterinary medicine, as well as from studies in various environmental compartments (soil, water, wastewater). All these activities are conducted according to different specifications and standards, which makes it difficult to compare data. A focus on AMR and MDRO of human therapeutic importance is helpful to provide some guidance. Most data are available across sectors on methicillin-resistant Staphylococcus aureus (MRSA) and multiresistant Enterobacterales such as Escherichia coli and Klebsiella pneumoniae. Here, the trends of resistance are heterogeneous. Antibiotic use leads to MRE selection, which is well documented. Success in minimizing antibiotic use has also been demonstrated in recent years in several sectors and could be correlated with success in containing AMR and MDRO (e.g., decrease in MRSA in human medicine). Sector-specific measures to reduce the burden of MDRO and AMR are also necessary, as not all resistance problems are linked to other sectors. Carbapenem resistance is still rare, but most apparent in human pathogens. Colistin resistance occurs in different sectors but shows different mechanisms in each. Resistance to antibiotics of last resort such as linezolid is rare in Germany, but shows a specific One Health correlation. Efforts to harmonize methods, for example in the field of antimicrobial susceptibility testing and genome-based pathogen and AMR surveillance, are an important first step towards a better comparability of the different data collections.